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Inflammatory bowel disease
AbsTrACT
Objectives Characterise the circulating inflammatory 
cytokine pattern among patients failing consecutive 
anti-tumour necrosis factor (anti-TNF) and anti-integrin 
treatments to identify predictors of response.
Methods A retrospective single-centre cohort study 
of 28 patients with inflammatory bowel disease (IBD) 
receiving anti-integrin therapy (vedolizumab) subsequent 
to the failure of anti-TNF treatment was conducted. Blood 
samples were obtained immediately prior to initiation 
of vedolizumab therapy, and the response to treatment 
was evaluated after completion of the 14-week induction 
regimen. Multiplex ELISA was applied to quantify 47 
preselected plasma proteins based on their putative 
involvement in the inflammatory process in IBD.
results Anti-TNF and vedolizumab non-responders 
(n=20) had significantly higher levels of circulating 
interleukin (IL)-6 than anti-TNF non-responders with 
subsequent response to vedolizumab (n=8): median 9.5 
pg/mL versus 5.9 pg/mL, p<0.05. Following stratification 
by diagnosis, patients with Crohn’s disease who failed 
vedolizumab therapy (n=7) had higher soluble CD40 
ligand (sCD40L) than responders (n=4): 153.0 pg/mL 
versus 45.5 pg/mL, p<0.01; sensitivity 100% (95% CI 
59% to 100%), specificity 100% (95% CI 40% to 100%). 
Osteocalcin was higher among patients with ulcerative 
colitis responding to vedolizumab (n=4) compared with 
those not responding (n=13): 4219 pg/mL versus 2823 pg/
mL, p=0.01; sensitivity 85% (95% CI 55% to 98%), 
specificity 100% (95% CI 40% to 100%).
Conclusions Patients with IBD failing vedolizumab 
induction and anti-TNF therapy have persistent IL-6 
pathway activity, which could be a potential alternative 
treatment target. sCD40L, osteocalcin and the IL-6 
pathway activity might be predictors for response to 
vedolizumab.
IntroductIon
Treatment of inflammatory bowel disease 
(IBD) has been revolutionised by the intro-
duction of therapeutic antibodies against 
tumour necrosis factor (TNF)-α. However, 
more than half of patients are refractory to 
this treatment or lose effect over time.1–3 
Within recent years, an effective alternative to 
anti-TNF treatment has become available with 
the advent of the integrin-targeting antibody, 
vedolizumab, a monoclonal anti-α4β7 inte-
grin antibody.4 5 Vedolizumab binds to α4β7 
expressed on a subset of primed gut-homing 
T-lymphocytes. The direct blocking and 
later endocytosis of α4β7 prevents lympho-
cyte adherence and diapedesis through the 
mucosal vascular addressin cell adhesion 
molecule (MAdCAM)-1 selectively expressed 
on gut endothelium.6 7 Restriction of leuco-
cyte diapedesis thereby limits intestinal 
immune cell infiltration and inflammation 
in both ulcerative colitis (UC) and Crohn’s 
disease (CD).4 5 8 9 Vedolizumab is used both 
as a first-line biological in IBD, but most 
frequently as second or third-line biological 
therapy in patients failing anti-TNF therapy. 
Although clinical trials with vedolizumab 
summary box
What is already known about this subject?
 ► A significant proportion of patients with inflamma-
tory bowel disease (IBD) do not respond adequately 
to vedolizumab, an observation that is in line with 
other biological therapies like the tumour necrosis 
factor (TNF) inhibitors.
 ► Prediction of response to vedolizumab therapy prior 
to initiation of therapy is currently not possible.
 ► Multiple inflammatory pathways drive IBD, indicat-
ing that both ulcerative colitis (UC) and Crohn’s dis-
ease (CD) are heterogeneous conditions.
What are the new findings?
 ► In this pilot study, we identified interleukin-6 to be a 
potential marker of non-response to vedolizumab in 
anti-TNF non-responsive patients with IBD.
 ► Soluble CD40 ligand and osteocalcin are additionally 
identified as potential markers for vedolizumab re-
sponsiveness in CD and UC, respectively.
How might it impact on clinical practice in the 
foreseeable future?
 ► Identifying predictors of response to vedolizumab 
therapy in patients with IBD might enable clinicians 
to personalise therapy based on the individual pa-
tient’s inflammatory profile.
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have proven efficacy in IBD, both with and without 
previous failure to anti-TNF therapy, some patients will 
not respond to treatment (primary non-responders). 
The risk of primary non-response is—as with other 
biologicals—higher among patients previously exposed 
to biologicals compared with bio-naïve patients.10 11 
Initial lack or subsequent loss of response to biolog-
ical therapy may be affected by: (1) non-immune-me-
diated pharmacokinetic issues due to insufficient drug 
doses resulting in inadequate tissue concentrations for 
proper drug efficacy; (2) immune-mediated pharmaco-
kinetic issues with development of antidrug antibodies 
causing rapid degradation of the drug and/or allergic 
reactions; or (3) pharmacodynamic issues character-
ised by predominant inflammatory pathways not being 
targeted by the drug.12 13 With the observation of gener-
ally adequate circulating vedolizumab through levels 
for full target occupancy during ongoing therapy, lack 
of treatment efficacy is most likely due to pharmaco-
dynamic rather than pharmacokinetic issues.14 On the 
contrary, successful reports of dose escalation due to lack 
of response following 6 weeks or 8 weeks of vedolizumab 
therapy indicates that pharmacokinetics and trough 
levels are important parameters influencing response.15 16
To explore this matter, and to identify markers for 
effectiveness of vedolizumab therapy, this pilot study 
was conducted to investigate the pattern of key circu-
lating inflammatory mediators in all available patients 
with IBD following failure to anti-TNF therapy and prior 
to initiation of vedolizumab therapy at our East Danish 
IBD centre. All patients were subsequently classified as 
responders or non-responders to vedolizumab, and these 
groups were compared.
Methods
study population
This retrospective single-centre cohort study included all 
available patients refractory to one or more anti-TNF ther-
apies who were subsequently initiated on vedolizumab in 
the period from the approval of vedolizumab until end of 
2016. A blood sample was obtained prior to initiation of 
vedolizumab therapy (median 8 days prior to first vedoli-
zumab administration, IQR 0–14 days). Ongoing inflam-
mation was confirmed by endoscopy prior to initiation of 
vedolizumab in all except four patients (86%), supported 
by clinical disease activity score in all patients (for UC 
median Mayo score 6, IQR 6–8.5, and for CD median 
Harvey-Bradshaw Index (HBI) 10, IQR 8–14).17 18 The 
disease activity defined by the Mayo score was: a score 
below 2 (no subscore above 1): inactive; 3–5: mild; 6–10: 
moderate; and 11–12: severe UC;, and the HBI: a score of 
0–4: inactive; 5–8: mild; 9–16: moderate; and >16: severe 
CD.
Effect of vedolizumab was evaluated at week 14, that 
is, at the end of the induction phase, based on changes 
in the disease activity indices mentioned above for UC 
and CD, respectively. As some patients with CD have 
been reported to have an extended response time to 
vedolizumab, the evaluation period of these partial 
responding patients was extended until week 20 to allow 
a clear determination of response. Based on this proce-
dure, three partial responding patients with CD obtained 
adequate effect of vedolizumab and were characterised as 
responders.4 5 11 Thus, primary non-response for patients 
with UC was defined as a total Mayo score decrease of ≤2 
points (or <30%) from baseline, with a rectal bleeding 
score decreased by 0 or an absolute rectal bleeding 
score >1. For patients with CD, primary non-response 
was defined as a decrease of ≤2 points from baseline. 
Measurements of individual predefined plasma proteins 
were compared between vedolizumab responders and 
non-responders in the IBD cohort. The statistical evalu-
ation of the patients was initially performed collectively 
for patients with IBD to increase statistical power in the 
limited dataset. The patients were afterwards segregated 
based on diagnosis into patients with UC and CD.
Blood sampling
Peripheral venous blood samples were drawn in EDTA 
(Greiner Bio-One, Kremsmünster, Austria). Samples 
were centrifuged at 2500 g for 5 min at ambient tempera-
ture to obtain plasma, which was aliquoted and stored at 
−80°C until analysis.
Multiplex eLIsA
Measurements of plasma proteins were conducted in 
duplicate using two separate Bio-Plex Pro plates (Bio-Rad 
Laboratories, Hercules, California, USA) without freeze/
thaw cycles. The applied plates were the Bio-Plex Pro 
Human Inflammation Panel 1, 37-Plex (171AL001M) 
measuring: APRIL/TNFSF13, BAFF/TNFSF13B, sCD30/
TNFRSF8, sCD163, chitinase-3-like 1, gp130/sIL-6Rβ, 
IFN-α2, IFN-β, IFN-γ, IL-2, sIL-6Rα, IL-8, IL-10, IL-11, 
IL-12 (p40), IL-12 (p70), IL-19, IL-20, IL-22, IL-26, IL-27 
(p28), IL-8A/IFN-λ2, IL-29/IFN-λ1, IL-32, IL-34, IL-35, 
LIGHT/TNFSF14, MMP-1, MMP-2, MMP-3, osteocalcin, 
osteopontin, pentraxin-3, sTNF-R1, sTNF-R2, TSLP and 
TWEAK/TNFSF12 as well as the Bio-Plex Pro Human 
Th17 Cytokine Panel 15-Plex (171AA001M) measuring: 
IL-1β, IL-4, lL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, 
IL-25, IL-31, IL-33, IFN-γ, sCD40L and TNF-α. Sample 
preparation was carried out according to the manufactur-
er’s recommendations. Measurements were performed 
on the Bio-Plex 200 instrument and the Bio-Plex Manager 
software, V.6.0 (Bio-Rad). In the case of overlapping 
analytes between the plates, the 37-plex was used for the 
analyses.
Measurements were included in the analysis when 
lying within the range of detection as specified by the 
manufacturer. Results were based on the performed stan-
dard curve spanning from lower level of quantification 
to upper level of quantification, while intra-assay coeffi-
cients of variation were below 20%. All concentrations 
are expressed in pg/mL after correcting for dilution. In 
total, 47 fully or partially measured plasma proteins were 
copyright.
 o
n
 7 M
ay 2019 by guest. Protected by
http://bmjopengastro.bmj.com/
BM
J O
pen G
astroenterol: first published as 10.1136/bmjgast-2018-000208 on 31 May 2018. Downloaded from 
 3Soendergaard C, et al. BMJ Open Gastro 2018;5:e000208. doi:10.1136/bmjgast-2018-000208
Open Access
included in the analysis, however, with ‘IL-27 (p28)’ and 
‘LIGHT’ being below detection limit.
Independent cohort from public database
From the GEO database (www. ncbi. nlm. nih. gov/ geo/), 
the GSE73661 study was extracted. That study contains 
microarray expression data from inflamed colonic intes-
tinal biopsies of patients with UC prior to initiation of 
vedolizumab. Data were generated using the Human 
Gene 1.0 ST array (Affymetrix, Santa Clara, California, 
USA) and were normalised (robust multichip average) 
as described in the study entry. Patients were separated 
based on the reported clinical efficacy of vedolizumab 
induction therapy, and selected transcripts were evalu-
ated using Mann-Whitney U tests as described below.
statistics
The statistical modelling tools, principal component 
analysis (PCA) and orthogonal projections to latent 
structures discriminant analysis (OPLS-DA), were initially 
performed on all data in an attempt to catch separating 
trends in the multidimensional dataset (performed in R, 
V.3.3.3, using the ‘Ropls’ package). As no models could be 
established using this approach, a conventional compar-
ison of responders and non-responders was performed 
using the two-tailed non-parametric Mann-Whitney U 
tests of continuous variables (performed in R) to iden-
tify group differences. Calculation of receiver operating 
characteristic (ROC) curve statistics and demographic 
data was performed in GraphPad Prism (GraphPad Soft-
ware (V.7), La Jolla, California, USA). Error bars repre-
sent median values with IQR. Statistical significance was 
defined as a p value below 0.05.
resuLts
study population
The demographic data of the study population is 
presented in table 1. Responders and non-responders 
to vedolizumab were overall comparable, except that 
among patients with CD a higher disease score and 
higher levels of C reactive protein (CRP) were observed 
among non-responders than in responders. Additionally, 
patients with CD responding to vedolizumab were older 
than non-responders, and responders in general (UC 
and CD collectively) had longer disease duration than 
non-responders.
PcA and oPLs-dA analysis
Initial PCA analysis and subsequent OPLS-DA calcula-
tion were performed on the entire dataset for identi-
fying predictive principle components for separation of 
responders and non-responders to vedolizumab induc-
tion treatment. This was done both in patients with IBD 
and subsequently in patients stratified by UC or CD, 
respectively. These calculations were, however, unable 
to generate any models for this separation based on the 
measured plasma proteins.
deregulated plasma protein levels in vedolizumab 
responders versus non-responders with IBd
Circulating interleukin (IL)-6 in plasma was significantly 
higher among non-responders than in responders to 
vedolizumab induction therapy: median 9.5 pg/mL 
versus 5.9 pg/mL, p<0.05. Furthermore, osteocalcin was 
higher in responders compared with non-responders: 
median 3627 pg/mL versus 2832 pg/mL, p=0.01 
(figure 1). Additionally, a weak trend of higher plasma 
levels of soluble gp130 among responders was observed 
(median 17 630 pg/mL vs 15 719 pg/mL, p=0.09).
deregulated plasma protein levels in vedolizumab 
responders versus non-responders with uc or cd
Circulating plasma protein levels between vedolizumab 
induction responders and non-responders among 
patients with UC or CD, respectively, was additionally 
explored. The soluble CD40 ligand (sCD40L) was higher 
in non-responding patients with CD (153.0 pg/mL vs 
45.5 pg/mL, p<0.01), whereas osteocalcin was higher in 
responders with UC (median 4219 pg/mL vs 2823 pg/
mL, p=0.01) (figure 2).
Using ROC curve statistics, the ability of the identi-
fied plasma proteins to predict response to vedolizumab 
was evaluated. Figure 3 shows the results, including 
area under the curve (AUC), the applied threshold, 
the calculated sensitivity and specificity, as well as the 
likelihood ratio for each of the four identified plasma 
proteins. When evaluating the identified disease-spe-
cific markers, sCD40L provided a complete separation 
of CD responders from non-responders (AUC=1, sensi-
tivity 100% (95% CI 59% to 100%), specificity of 100% 
(95% CI 40% to 100%)), whereas osteocalcin provided a 
model for separating UC responders and non-responders 
to vedolizumab (AUC=0.92, sensitivity 85% (95% CI 
55% to 98%), specificity 100% (95% CI 40% to 100%)) 
(figure 3).
confirmatory data from an independent cohort
Transcriptomic microarray data from colonic biopsies 
from bio-naïve patients with UC prior to vedolizumab 
initiation, with information on subsequent response, was 
available through the Gene Expression Omnibus data-
base accession number GSE73661.19 The patients were 
classified as responders (n=10) or non-responders (n=26) 
at later follow-up. Using this dataset, we confirmed an 
upregulation of IL-6 among non-responders (median 
6.8, IQR 5.2–7.9) as compared with responders (5.3; 
4.9–6.4) (p<0.05) (Log2 expression values). Nevertheless, 
osteocalcin, sCD40L and gp130 were equally expressed 
among responders and non-responders to vedolizumab 
induction therapy in this dataset.
dIscussIon
Some patients with IBD on biological therapy, both 
with anti-TNF and anti-integrins, fail treatment over 
time.1 2 10 20 Making an active decision to change class 
of therapy or to apply add-on therapies is therefore 
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important for targeting the specific disease driving path-
ways in clinical settings.21–23 In the current single centre 
pilot study, all included patients were refractory to TNF 
inhibitors, indicating that TNF-α is not the primary inflam-
matory pathway in this cohort. By the current approach, 
we aimed to identity alternative drivers of inflammation 
and to assess the predictability of responsiveness to vedol-
izumab in IBD based on plasma samples—a routinely 
obtained and easily analysable approach in daily practice.
Plasma measurements provide a fingerprint of released 
inflammation-related mediators and those resulting 
from spillover from the inflamed intestine, thus being 
Table 1 Disease characteristics and demographic data of patients, divided by response to vedolizumab
Responders to VDZ,
n=8
Non-responders to VDZ,
n=20 P values, IBD
Gender (male/female) 2/6 10/10 P=0.23∆
UC: 2/2 UC: 8/5 UC: P=0.68
CD: 0/4 CD: 2/5 CD: P=0.24
Age (median, range) 42 (23–59) 39 (18–62) P=0.85ᵒ
UC: 34 (23-44) UC: 42 (27-62) UC: P=0.16
CD: 49 (32-59) CD: 30 (18-53) CD: P<0.05
Disease score prior to VDZ initiation 
(median, range)
– – – ᵒ
  UC: Mayo score UC: 8 (6 – 12) UC: 6 (4–9) UC: P=0.15
  CD: HBI score CD: 8 (7–9) CD: 11 (10-16) CD: P<0.01
Disease duration, years (median, range) 17 (7–41) 7 (1–17) P<0.05ᵒ
UC: 8 (7–25) UC: 5 (1–16) UC: P=0.11
CD: 22 (12-41) CD: 12 (5-17) CD: P=0.058
Current or past smoking (yes/no) 2/6 5/15 P=0.99 ∆
UC: 2/2 UC: 5/8 UC: P=0.68
CD: 0/4 CD: 0/7 CD: P=ND
CRP, mg/L (median, range) 0 (0–4) 3.5 (0–107) P<0.05 ᵒ
UC: 0 (0–3) UC: 3 (0–17) UC: P=0.40
CD: 0 (0–4) CD: 15 (4-107) CD: P<0.01
Concurrent systemic steroid treatment 
(yes/no)
1/7 5/15 P=0.47 ∆
UC: 1/3 UC: 5/8 UC: P=0.62
CD: 0/4 CD: 0/7 CD: P=ND
Concomitant therapy; 5-ASA, thiopurine or 
methotrexate (yes/no)
4/3 5/15 P=0.12 ∆
UC: 3/1 UC: 12/1 UC: P=0.35
CD: 1/3 CD: 4/3 CD: P=0.30
Previous surgery (partial resection, colonic 
or ileocecal) (yes/no)
1/7 4/16 P=0.64 ∆
UC: 0/4 UC: 0/13 UC: P=ND
CD: 1/3 CD: 4/3 CD: P=0.30
Intestinal disease location UC: P=0.70∆
CD: P=0.91
  UC/Proctitis 2 5 –
  UC/Left-sided colitis 0 2 –
  UC/Pancolitis 2 6 –
  CD/Colon only 2 4 –
  CD/Ileocolonic 1 2 –
  CD/Ileum only 1 1 –
∆χ2 square test.
ᵒMann-Whitney U test.
5-ASA, 5-aminosalicylic acid; CD, Crohn’s disease; CRP, C reactive protein; ND, cannot be calculated; UC, ulcerative colitis; VDZ: 
vedolizumab.
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influenced by disease severity and spatial extension. 
As a central inflammatory mediator, IL-6 is involved in 
immune cell activation, recruitment and the acute phase 
response.24 Along with higher circulating levels of IL-6 
among non-responders to vedolizumab, we observed a 
trending increase of gp130 in responders as compared 
with non-responders (figure 1). IL-6 and gp130 are 
inter-related as transmembrane gp130 complexes with 
the IL-6 receptor (IL-6R) to form the functional IL-6R 
complex. Signalling mediated by IL-6 can occur through 
two mechanisms: (1) direct signalling via the IL-6R 
complex occurs on cells expressing the IL-6R. In these 
cells, IL-6 induces proinflammatory effects, promoting 
cellular activation, recruitment and survival.25 Further-
more, IL-6 is known to be important for T helper 
(Th) 1-mediated intestinal inflammation.26 27 (2) Alterna-
tive IL-6 signalling, or transactivation, occurs when IL-6 
binds soluble IL-6R originating from proteolytic receptor 
cleavage or from alternative splicing.28 The circulating 
IL-6/IL-6R complex can subsequently bind the ubiqui-
tously expressed gp130 and induce IL-6-like signalling 
in cells not expressing the IL-6R. Soluble gp130 can 
Figure 1 Plasma protein levels in responders and non-responders in patients with IBD. The two plasma proteins IL-6 and 
osteocalcin were found at significantly different levels among patients with IBD responding to vedolizumab as compared with 
non-responders. Although gp130 was not statistically significantly deregulated, it showed a trend for higher levels among 
responders. IBD, inflammatory bowel disease; IL-6, interleukin-6; NR, non-responders; R, responders.
Figure 2 Plasma protein levels in responders and non-responders in patients with CD and UC, respectively. In CD, soluble 
CD40 ligand (sCD40L) was measured in higher levels among non-responders to vedolizumab, and a higher level of osteocalcin 
was observed in patients with UC responding to vedolizumab. CD, Crohn’s disease; NR, non-responders; R, responders; UC, 
ulcerative colitis.
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bind the formed IL-6/IL-6R complex and antagonise 
the IL-6 transactivation.29 This point has already been 
confirmed in vitro and in IBD with increased levels of 
soluble gp130.30 In experimental colitis, disease severity 
is additionally alleviated by gp130 administration.31 
The complexity of IL-6 signalling during inflammation, 
however, makes any definite conclusions elusive. Our 
finding that primary non-responders to vedolizumab 
have increased levels of IL-6 and trending lower levels of 
soluble gp130 as compared with responders indicates an 
overall increased IL-6 pathway activity, both via the clas-
sical and the alternative pathways, and also by a limited 
antagonistic capacity. Nevertheless, the biological signif-
icance of this observation needs to be confirmed and 
explored in other and larger cohorts.
Previous findings of elevated IL-6 levels in anti-TNF 
refractory patients indicate a role for IL-6 in TNF-α-in-
dependent inflammation.32 33 In addition, enhanced 
mucosal gene expression of IL-6 was observed in a dataset 
from bio-naïve patients with UC being non-responders to 
vedolizumab.19 This is of special interest, since the IL-6 
pathway by definition has not been targeted by any prior 
anti-TNF treatments among the patients studied, thus 
suggesting that patients with hyperactive IL-6 signalling 
may favourably be treated using non-TNF, non-α4β7 
integrin blocking strategies. This finding might further 
be supported by a recent study in IBD as well as exper-
imental colitis showing that inflammation involving the 
cytokine oncostatin M and IL-6 is capable of driving a 
TNF-independent intestinal inflammation.33 34
Whereas several studies have evaluated the effects of 
blocking IL-6 signalling during inflammatory conditions, 
including the compounds tocilizumab, C326, oloki-
zumab, clazakizumab, and PF-04236921, only two studies 
have so far investigated this matter successfully in IBD, 
specifically in CD. Here positive effects on disease severity 
and induction of remission were observed as compared 
with controls.35 36 This observation might support the 
involvement of IL-6 in anti-TNF and anti-integrin refrac-
tory inflammation.
In the present study, higher levels of sCD40L were 
observed in non-responders to vedolizumab (figure 2). 
The functions of the CD40/CD40L-axis and its specific 
relation to IBD have previously been extensively 
reviewed.37 Briefly, CD40L is expressed on activated 
T cells but can also be expressed by additional immune 
Figure 3 Comparing plasma biomarkers for predicting response to vedolizumab using ROC curve statistics. The ability 
of the four identified markers for predicting response to vedolizumab was tested. By calculation of area under the curve 
(AUC), sensitivity (sens), specificity (spec) and likelihood ratio (LHR), the ability of IL-6 and osteocalcin to predict response 
to vedolizumab in patients with IBD was assessed. Furthermore, sCD40L and osteocalcin were evaluated in patients with 
CD and UC, respectively. CD, Crohn’s disease; IBD, inflammatory bowel disease; IL-6, interleukin-6; ROC, receiver operating 
characteristic; sCD40L, soluble CD40 ligand; UC, ulcerative colitis.
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cells upon inflammatory stimulation and activation.38–40 
It interacts with CD40 expressed by a variety of immune 
and non-immune cells, especially antigen-presenting 
cells, where it induces general cellular activation and 
cytokine secretion.37 41 42 In IBD, an augmented mucosal 
expression of both CD40 and CD40L was observed 
together with increased levels of circulating sCD40L.43–48 
In two in vivo models, antibody-mediated blockage of 
CD40/CD40L effectively alleviated inflammation. These 
studies emphasise the importance of CD40L signalling in 
the pathogenesis of IBD, as targeting this signalling may 
prevent Th1 T cell priming.49 50 In fact, we found sCD40L 
to be increased in non-responders as compared with 
responders in CD only, which is classically described as a 
Th1-driven disease versus the Th2-driven UC. This obser-
vation supports the notion of an impact on Th1-driven 
inflammation and might additionally indicate a more 
aggravated immune activation in the group of non-re-
sponders to vedolizumab revealed in this study.46 47
As predictive parameters for vedolizumab response, 
we evaluated IL-6 and osteocalcin for IBD, and sCD40L 
and osteocalcin for CD and UC, respectively, as depicted 
in figure 3. The best surrogate markers for vedolizumab 
response were the disease-specific markers, presenting 
predictive models with high AUC values in this cohort. 
Besides sCD40L, as described above, osteocalcin is synthe-
sised by osteoblasts and is a marker for bone formation 
that correlates with bone mineral density, although 
the past decade has provided evidence for endocrine 
functions of osteocalcin in glucose and energy homeo-
stasis.51 52 The measurement of higher osteocalcin levels 
among responders might indicate a less severe and/
or shorter duration of the inflammation as compared 
with non-responders, and thus a sparring of the bones. 
A specific influence of osteocalcin on the inflammatory 
process does not appear to exist.
The present cohort, where 20 of 28 patients (71%, 
95% CI 51.3 to 86.8) were non-responders, might not 
reflect the efficacy of vedolizumab in general.4 5 10 53 This is 
due to the fact that all of the included patients had previ-
ously failed at least one biological agent and that some 
patients had been waiting for vedolizumab to reach the 
market (Q2 in 2014) before initiation of this therapeutic 
approach. Failures to biologicals are well-known hard-to-
treat patients, and treatment responses to any biological 
in this cohort are expected to be low.3 54 Along with a low 
sample size, this might explain the rather high rate of 
non-responders in the present study. In patients showing 
partial response to vedolizumab induction therapy, a 
shortened dosing interval of one or several doses was 
initiated to ensure adequate drug levels, although these 
were not measured. Half the patients received dose(s) at 
shorter intervals as recommended by a previous study.15
The existence of non-responders points to the pres-
ence of yet alternative pathways driving inflammation 
and immune cell recruitment in patients with IBD who 
are unresponsive to anti-TNF and anti-α4β7 treatments. 
It appears that hindering of leucocyte recruitment using 
vedolizumab through α4β7–MAdCAM-1 blocking may 
allow compensation of immune cell diapedesis through 
additional integrin systems, at least in some patients. 
These include: leucocyte VLA4 (α4β1) binding to endo-
thelial vascular cell adhesion molecule  (VCAM)-1, leuco-
cyte αEβ7 binding to epithelial E-cadherin, and leucocyte 
LFA-1 (αLβ2) binding to endothelial intercellular adhe-
sion molecule (ICAM)-1 and 2.55–57 Thus, compensatory 
regulation of homing molecules may lead to both a main-
tained leucocyte infiltration and potentially to changes 
in intestinal leucocyte populations with yet unknown 
consequences for the disease course in non-responders 
to vedolizumab.
In the sparse published attempts to predict response to 
vedolizumab, a combination of baseline clinical param-
eters and microbial taxonomy data yielded predictive 
models for UC, CD and IBD, all with AUC values above 
0.85 (sensitivity >85%, specificity >75%).58 A related 
study based on clinical variables and faecal calprotectin 
following 6 weeks of treatment could predict (AUC value 
0.73 (95% CI 0.65 to 0.82)) steroid-free remission at 
week 52.59 Another study has shown that a lower base-
line frequency of α4β7-positive CD4 T cell in patients 
with IBD was associated with clinical response to vedoli-
zumab. Additionally, this study revealed that expressional 
changes in T cell α4β1 at week 6 of vedolizumab treat-
ment could predict the response at week 14 with both a 
sensitivity and a specificity of 100%.57 On the contrary, 
another study found higher basal α4β7 expression on 
CD4 and CD8 T cells as well as natural killer cells from 
responders compared with non-responders. It was addi-
tionally shown that saturation of the α4β7 receptor 
during maintenance therapy could be a potential marker 
for vedolizumab response.60 Finally, mucosal gene expres-
sion profiles from responders and non-responders were 
evaluated, but these were unable to predict the response 
to vedolizumab in UC.19
Identification of predictive markers for response to 
vedolizumab or other biologicals might significantly 
improve the treatment strategy of this group of patients 
by limiting inefficient therapeutic approaches. With the 
resulting economic benefits and, importantly, improved 
guidance of effective therapy, such markers could reduce 
the duration of flaring disease and lower the risk for 
surgical intervention among these patients. Identifica-
tion of prognostic markers for response to therapy still 
lies in academia, although progress is being made as 
detailed above.
Our study has some important limitations. Although all 
available patients were included in this East Danish single-
centre study, the sample size was limited. The initial eval-
uation was performed in patients with IBD collectively 
to increase power of the calculations. Accordingly, we 
believe that the findings presented need to be considered 
exploratory and that validation of our findings needs to 
be confirmed in larger and independent patient cohorts. 
As a selected set of a priori known inflammation-related 
markers were chosen in the present exploratory study, 
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correction for multiple testing was not performed. Within 
the study population, we observed a somewhat higher HBI 
score and elevated CRP levels among patients with CD and 
vedolizumab treatment failure, which induces a risk for 
disease severity as a confounding factor for the observed 
differences of plasma protein levels (table 1). However, 
the fact that we were able to confirm the main findings 
in another and larger cohort of bio-naïve vedolizum-
ab-treated patients19 strongly substantiate the validity of the 
novel results provided here. Future studies should include 
endoscopic evaluation of the patients after vedolizumab 
induction therapy and should in addition include mucosal 
healing as a parameter for response. Blood sampling 
following the vedolizumab induction therapy should also 
be considered to verify normalisation of the identified 
markers in patients responding to the therapy.
In conclusion, this exploratory study indicates that the 
IL-6 signalling pathway may play an important role in 
driving persistent inflammation in anti-TNF and anti-in-
tegrin refractory patients with IBD. Furthermore, it seems 
that circulating levels of IL-6, sCD40L, and osteocalcin may 
represent possible predictors of later response to vedoli-
zumab therapy in IBD. These observations, however, need 
to be confirmed in larger and independent cohorts.
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